"Bangladesh Pharmaceuticals & Healthcare Report Q4 2015" Published

Private consumption growth in Bangladesh will continue to gather momentum, contributing to the pharmaceutical and healthcare sector expansion. In addition, the recent increase in the government budget for health will translate in improved access to healthcare services, including in rural areas, prioritizing investments in infrastructure and tele medicine . While the sector will present substantial growth potential over the next decade given rising incomes and higher levels of urbanisation, low per capita spending on medicines will ensure that generic medicines continue to account for the largest market share, albeit this figure is expected to gradually moderate due to improving access to innovative pharmaceuticals .

Full Report Details at
- http://www.fastmr.com/prod/1047911_bangladesh_pharmaceuticals.aspx?afid=301

Headline Expenditure Projections

Pharmaceuticals: BDT154.24bn (USD1.99bn) in 2014 to BDT171.62bn (USD2.19bn) in 2015; +11.27% in local currency terms and +10.35% in US dollar terms. Forecast revised upwards from last quarter.

Healthcare: BDT437.86bn (USD5.65bn) in 2014 to BDT494.03bn (USD6.32bn) in 2015; +12.8% in local currency terms and +11.9% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index: In Q415 Bangladesh RRI score remains stable at 41.8 (out of 100). Bangladesh also retains its ranking position in our RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh's score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

The Bangladesh Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladesh pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Bangladesh, to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
* Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
* Assess the activities, strategy and market position of your competitors

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015